Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives

IntroductionDiffuse Low-grade gliomas (DLGG, WHO Grade II) are a heterogenous group of tumors comprising 13–16% of glial tumors. While maximal safe resection is endorsed as the best approach to DLGG, compared to more conservative interventions like stereotactic biopsy, the added costs and risks have...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Kyle Tuohy, Djibril M. Ba, Debarati Bhanja, Douglas Leslie, Guodong Liu, Alireza Mansouri
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2023-02-01
Rangatū:	Frontiers in Surgery
Ngā marau:	low-grade glioma (WHO grade II) cost resection stereotactic biopsy adverse events—complications MarketScan database
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fsurg.2023.1001741/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!